Laboratory tests for antithrombin deficiency

American Journal of Hematology

Volumn 85, Issue 12, 2010, Pages 947-950

  Khor, Bernard ^a   Van Cott, Elizabeth M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; ORAL CONTRACEPTIVE AGENT; THROMBIN INHIBITOR;

ANTITHROMBIN DEFICIENCY; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; GENETIC DISORDER; HUMAN; IMMUNOASSAY; LABORATORY TEST; PRIORITY JOURNAL; RISK FACTOR; VEIN THROMBOSIS;

ANTITHROMBIN III DEFICIENCY; ANTITHROMBINS; DIAGNOSIS, DIFFERENTIAL; FALSE NEGATIVE REACTIONS; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES;

EID: 78649524580     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21893     Document Type: Article

References (42)

1. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-3544.
2. Melissari E, Monte G, Lindo VS, et al. Congenital thrombophilia among patients with venous thromboembolism. Blood Coagul Fibrinolysis 1992; 3: 749-758.
3. Picard V, Nowak-Gottl U, Biron-Andreani C, et al. Molecular bases of antithrombin deficiency: Twenty-two novel mutations in the antithrombin gene. Hum Mutat 2006; 27: 600.
4. Rodeghiero F, Tosetto A. The epidemiology of inherited thrombophilia: The VITA Project. Vicenza Thrombophilia and Atherosclerosis Project. Thromb Haemost 1997; 78: 636-640.
5. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112.
6. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med 1992; 116: 754-761.
7. Kottke-Marchant K, Duncan A. Antithrombin deficiency: Issues in laboratory diagnosis. Arch Pathol Lab Med 2002; 126: 1326-1336.
8. van der Meer FJ, Koster T, Vandenbroucke JP, et al. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 631-635.
9. Vossen CY, Conard J, Fontcuberta J, et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost 2004; 2: 1526-1532.
10. Mahmoodi BK, Brouwer JL, Veeger NJ, van der Meer J. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: Results from a large family cohort study. Circulation 2008; 118: 1659-1667.
11. Duhl AJ, Paidas MJ, Ural SH, et al. Antithrombotic therapy and pregnancy: Consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007; 197: 457, e451-e421.
12. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112: 19-27.
13. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: New therapeutic implications. Semin Thromb Hemost 1998; 24: 27-32.
14. Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. For the plasma coagulation inhibitors subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis. Thromb Haemost 1997; 77: 197-211.
15. Rossi E, Chiusolo P, Za T, et al. Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): Demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk. Thromb Haemost 2007; 98: 695-697.
16. Lane DA, Olds RJ, Conard J, et al. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest 1992; 90: 2422-2433.
17. Girolami A, Lazzaro AR, Simioni P. The relationship between defective heparin cofactor activities and thrombotic phenomena in AT III abnormalities. Thromb Haemost 1988; 59: 121.
18. Wells PS, Blajchman MA, Henderson P, et al. Prevalence of antithrombin deficiency in healthy blood donors: A cross-sectional study. Am J Hematol 1994; 45: 321-324.
19. Demers C, Henderson P, Blajchman MA, et al. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993; 69: 231-235.
20. Ungerstedt JS, Schulman S, Egberg N, et al. Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: Do factor Xa-based methods overestimate antithrombin activity in some patients? Blood 2002; 99: 2271-2272.
21. Odegard OR, Lie M, Abildgaard U. Antifactor Xa activity measured with amidolytic methods. Haemostasis 1976; 5: 265-275.
22. Sas G, Pepper DS, Cash JD. Further investigations on antithrombin III in the plasmas of patients with the abnormality of antithrombin III Budapest. Thromb Diath Haemorrh 1975; 33: 564-572.
23. Downing MR, Bloom JW, Mann KG. Comparison of the inhibition of thrombin by three plasma protease inhibitors. Biochemistry 1978; 17: 2649-2653.
24. Meijer P, Kluft C, Haverkate F, De Maat MP. The long-term within- and between-laboratory variability for assay of antithrombin, and proteins C and S: Results derived from the external quality assessment program for thrombophilia screening of the ECAT Foundation. J Thromb Haemost 2003; 1: 748-753.
25. Bayston TA, Lane DA. Antithrombin: Molecular basis of deficiency. Thromb Haemost 1997; 78: 339-343.
26. Corral J, Hernandez-Espinosa D, Soria JM, et al. Antithrombin Cambridge II (A384S): An underestimated genetic risk factor for venous thrombosis. Blood 2007; 109: 4258-4263.
27. Antithrombin Mutation Database, available at:
28. Liebman HA, Wada JK, Patch MJ, McGehee W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer 1982; 50: 451-456.
29. Cakal B, Gokmen A, Yalinkilic M, et al. Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease. Blood Coagul Fibrinolysis 2010; 21: 118-121.
30. Rao AK, Niewiarowski S, Guzzo J, Day HJ. Antithrombin III levels during heparin therapy. Thromb Res 1981; 24: 181-186.
31. Meade TW, Dyer S, Howarth DJ, et al. Antithrombin III and procoagulant activity: Sex differences and effects of the menopause. Br J Haematol 1990; 74: 77-81.
32. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-172.
33. Ling X, Delorme M, Berry L, et al. alpha 2-Macroglobulin remains as important as antithrombin III for thrombin regulation in cord plasma in the presence of endothelial cell surfaces. Pediatr Res 1995; 37: 373-378.
34. Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
35. Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006; 95: 362-372.
36. Iba T, Gando S, Murata A, et al. Predicting the severity of systemic inflammatory response syndrome (SIRS)-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma 2007; 63: 1093-1098.
37. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002; 30: S325-331.
38. Souter PJ, Thomas S, Hubbard AR, et al. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001; 29: 134-139.
39. Dunzendorfer S, Kaneider N, Rabensteiner A, et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 2001; 97: 1079-1085.
40. Oelschlager C, Romisch J, Staubitz A, et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002; 99: 4015-4020.
41. Toh CH, Samis J, Downey C, et al. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 2002; 100: 2522-2529.
42. Laposata M, Van Cott EM. How to work up hypercoagulability. CAP Today 2000; 14: 24-26.